CLDX vs TRIB
Celldex Therapeutics, Inc. and Trinity Biotech PLC, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CLDX | TRIB |
|---|---|---|
| Revenue | $1.5M | $61.6M |
| Net income | $-258.8M | $-31.8M |
| Gross margin | 87.1% | 34.8% |
| Net margin | −16748.0% | −51.6% |
| Return on equity | −40.6% | — |
| Diluted EPS | −$3.90 | — |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-213.7M | $-4.6M |
| Equity | $527.2M | — |
| Net debt / equity | −0.14× | — |
| Current ratio | 10.49× | 1.28× |
| Revenue CAGR 5y | −26.9% | −7.4% |
| Profit CAGR 5y | — | — |
TRIB bills 39.8× the revenue of CLDX, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | CLDX | TRIB |
|---|---|---|
| FY2024 | $7.0M | $61.6M |
| FY2023 | $6.9M | $56.8M |
| FY2022 | $2.4M | $62.5M |
| FY2021 | $4.7M | $81.1M |
| FY2020 | $7.4M | $102.0M |
| FY2019 | $3.6M | $90.4M |
| FY2018 | $9.5M | $97.0M |
| FY2017 | $12.7M | $99.1M |
| FY2016 | $6.8M | $99.6M |
| FY2015 | $5.5M | $100.2M |
Net income by year
Bottom line
| Fiscal year | CLDX | TRIB |
|---|---|---|
| FY2024 | $-157.9M | $-31.8M |
| FY2023 | $-141.4M | $-24.0M |
| FY2022 | $-112.3M | $-41.0M |
| FY2021 | $-70.5M | $875,000 |
| FY2020 | $-59.8M | $-6.4M |
| FY2019 | $-50.9M | $-28.9M |
| FY2018 | $-151.2M | $-22.1M |
| FY2017 | $-93.0M | $-40.3M |
| FY2016 | $-128.5M | $-100.6M |
| FY2015 | $-127.2M | $21.8M |
Advertisement
AdSense · Rectangle 336×280
More in this industry